Trial Profile
A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PACIFIC-5
- Sponsors AstraZeneca
- 19 Apr 2023 Planned End Date changed from 29 Nov 2024 to 16 Mar 2027.
- 19 Apr 2023 Planned primary completion date changed from 30 Apr 2023 to 21 Jun 2024.
- 04 Jan 2023 Planned primary completion date changed from 25 Nov 2022 to 30 Apr 2023.